2019

The Centers for Medicare and Medicaid Services (“CMS”) announced a final rule permitting Medicare Part B plans, including those…

The Centers for Medicare & Medicaid Services recently published its Annual Report to Congress on the Open Payments Program.…

The Trump administration recently issued new guidelines that will expand White House and congressional oversight and review of…

We have previously written about the law in Nevada requiring reporting for pharmaceutical representatives and the law that…

The US Supreme Court vacated and remanded a products liability case involving claims alleging a failure to warn about risks of…

As reported by Regulatory Focus, a new review of studies of direct-to-consumer (DTC) prescription drug advertising identifies…

In June 2017, the state of Oklahoma sued several pharmaceutical companies for their alleged roles in the state’s opioid epidemic.…

The Department of Health and Human Services (“HHS”) Office of Inspector General (“OIG”) provided its quarterly report on the…

The Department of Justice (“DOJ”) issued new guidance to its litigators on cooperation credit in False Claims Act cases. This new…

On April 4-5, 2019, the Medicare Payment Advisory Committee (“MedPAC”) held a public meeting in Washington, DC to discuss issues…